Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman(Harvard University), Nir Hacohen(Cambridge Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Genevieve M. Boland(Harvard University), Sangeetha M. Reddy(The University of Texas MD Anderson Cancer Center), Stacey L. Bjorgaard(Broad Institute), Keith T. Flaherty(Cancer Research Center), Carl G. de Boer(University of British Columbia), Russell W. Jenkins(Broad Institute), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Michal Barzily-Rokni(Shaare Zedek Medical Center), Paul Hoover(Broad Institute), Hans Vitzthum(Harvard University), Dennie T. Frederick(Broad Institute), Alexandra–Chloé Villani(Broad Institute), Marc R. Hammond(Harvard University), Cloud P. Paweletz(Massachusetts General Hospital), David A. Barbie(Dana-Farber Cancer Institute), David Lieb(Broad Institute), Samuel S. Freeman(Broad Institute), Jean-Pierre Eliane(Massachusetts General Hospital), Zachary A. Cooper(AstraZeneca (Singapore)), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Andrew Portell(Massachusetts General Hospital), Amir Reza Aref(Massachusetts General Hospital), Shauna Blackmon(Harvard University), Vancheswaran Gopalakrishnan(AstraZeneca (United States)), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Anat Stemmer‐Rachamimov(Massachusetts General Hospital), Bo Li(Children's Hospital of Philadelphia), Gad Getz(Broad Institute), Jonathan Chen(Broad Institute), Keren Yizhak(Broad Institute)
Cell
November 1, 2018
Cited by 2,037


Related Papers